Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan 5;122(1):14-16.
doi: 10.1161/CIRCRESAHA.117.312287.

Cardiac Cell Cycle Activation as a Strategy to Improve iPSC-Derived Cardiomyocyte Therapy

June-Wha Rhee  1 , Joseph C Wu  2
Affiliations
Editorial

Cardiac Cell Cycle Activation as a Strategy to Improve iPSC-Derived Cardiomyocyte Therapy

June-Wha Rhee et al. Circ Res. .
No abstract available

Keywords: Editorials; cell cycle; cell transplantation; heart failure; myocyte, cardiac; pluripotent stem cell.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Strategies to activate cardiac cell cycle activity for myocardial regeneration
Positive cell cycle regulators such as cyclin-CDK complexes facilitate cell cycle entry and progression. Overexpression (OE*) of cyclins have been shown to promote cell cycle activity. Treatments with various hormones, growth factors, microRNAs, or small molecules have also been used to 1) induce reentry into the cell cycle or 2) modulate activities of direct cell cycle regulators and their molecular correlates (e.g., tumor suppressor RB) along the various points of the cell cycle. BMP, bone morphogenetic protein; CDK, cyclin-dependent kinase; FGF, fibroblast growth factors; G-CSF, granulocyte colony stimulating factor; GSK3, glycogen synthase kinase 3; HASF, hypoxia-regulated Akt-mediated stem cell factor; IGF, insulin-like growth factor; miR, microRNA; RB, retinoblastoma; T3, triiodothyronine.
See this image and copyright information in PMC

Comment on

References

    1. Nguyen PK, Neofytou E, Rhee J-W, Wu JC. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review. JAMA Cardiol. 2016;1:953–962. - PMC - PubMed
    1. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11:855–860. - PMC - PubMed
    1. Hockemeyer D, Jaenisch R. Induced pluripotent stem cells meet genome editing. Cell Stem Cell. 2016;18:573–586. - PMC - PubMed
    1. Shiba Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y, Ogasawara T, Okada K, Shiba N, Sakamoto K, Ido D, Shiina T, Ohkura M, Nakai J, Uno N, Kazuki Y, Oshimura M, Minami I, Ikeda U. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 2016;538:388–391. - PubMed
    1. de Almeida PE, Ransohoff JD, Nahid A, Wu JC. Immunogenicity of pluripotent stem cells and their derivatives. Circ Res. 2013;112:549–561. - PMC - PubMed

Publication types